Bellerophon Therapeutics, Inc.

BLPH

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
BLPH
CIK0001600132
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address184 LIBERTY CORNER ROAD, SUITE 302, WARREN, NJ, 07059
Website bellerophon.com
Phone908-574-4770
CEOPeter Fernandes
Employees20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$5.64 million
Pre-Tax Income$-10.53 million
Net Income$-9.25 million
Net Income to Common$-9.25 million
EPS$-0.84
View All
Balance Sheet
Cash$4.38 million
Assets$4.98 million
Liabilities$1.26 million
Common Equity$3.72 million
Liabilities & Equity$4.98 million
View All
Cash Flow Statement
Calculations
NOPAT$-7.72 million
EBITDA$-11.03 million
Price to EarningsN/A
Price to Book$0.04
ROE-165.96%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $0.69, marking a -1.78% move from the previous day.

Article Link

Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know

Bellerophon Therapeutics (BLPH) closed the most recent trading day at $0.68, moving -1.93% from the previous trading session.

Article Link

7 Must-Have Stocks to Buy and Hold for a Secure Future

One reason we invest in the stock market is that we’re all looking to secure our financial futures. We want to be comfortable in our retirements and provide for our families and even future generations. Getting there means finding reliable buy and hold stocks for long-term portfolios. Warren Buffett, of course, is the acknowledged king of buy and hold stocks, or long-term investing. The Oracle of Omaha makes his fair share of trades, but his famed portfolio also includes many stocks he’s held fo

Article Link

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Article Link

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeu

Article Link